Ladostigil
Idi na navigaciju
Idi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| [(3R)-3-(prop-2-inilamino)indan-5-il]-N-propilkarbamat | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 209349-27-4 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 208907 | ||
| ChemSpider[3] | 181005 | ||
| UNII | SW3H1USR4Q 
| ||
| Hemijski podaci | |||
| Formula | C16H20N2O2 | ||
| Mol. masa | 272,34 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Sinonimi | [N-propargil-(3R)-aminoindan-5il]-N-propilkarbamat | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | Nije kontrolisan | ||
| Način primene | Oralno | ||
Ladostigil (TV-3,326) je neuroprotektivni agens koji se istražuje za moguću primenu u lečenju neurodegenerativnih poremećaja poput Alchajmerove bolesti, demencije sa Levijevim telima, i Parkinsonove bolesti.[4] On deluje kao reversiblni inhibitor acetilholinesteraze i butirilholinesteraze, i kao ireverzibilni inhibitor monoamiske oksidaze B. On kombinuje mehanizme dejstva starijih lekova kao što su rivastigmin i rasagilin u jedan molekul.[5][6] Osim neuroprotektivnih svojstava, ladostigil poboljšava izražavanje neurotrofnih faktora poput GDNF i BDNF, a moguće je da ima sposobnost povraćanja dela oštećenja prisutnih kod neurodegenerativnih bolesti putem indukcije neutrogeneze.[7] Ladostigil takođe ima antidepresivno dejstvo, i može da bude koristan pri lečenju depresije i anksioznosti.[8][9]
Reference[uredi - уреди | uredi izvor]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.
- ↑ Weinstock M, Bejar C, Wang RH et al. (2000). "TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease". Journal of Neural Transmission. Supplementum (60): 157–69. PMID 11205137.
- ↑ Weinreb O, Mandel S, Bar-Am O et al. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 163–74. PMID 19110207. doi:10.1016/j.nurt.2008.10.030.
- ↑ Weinstock M, Luques L, Bejar C, Shoham S (2006). "Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression". Journal of Neural Transmission. Supplementum (70): 443–6. PMID 17017566.
- ↑ Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences 1122: 155–68. PMID 18077571. doi:10.1196/annals.1403.011.
- ↑ Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology 160 (3): 318–24. PMID 11889501. doi:10.1007/s00213-001-0978-x.
- ↑ Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry 27 (4): 555–61. PMID 12787840. doi:10.1016/S0278-5846(03)00053-8.
Vidi još[uredi - уреди | uredi izvor]
Spoljašnje veze[uredi - уреди | uredi izvor]
| ||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
